Novartis

New phase 3 trial NCT05132075 posted by Novartis Pharmaceuticals: "Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer". New trial on a phase 3 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 12 days ago.

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.

New phase 1_2 trial NCT04699188 posted by Novartis Pharmaceuticals: "Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation". New trial on a phase 1_2 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 174 days ago.

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.